ASH 2025 | The potential of incorporating sBCMA & MTV data into clinical decision-making

In the era that we’re in now, the average community oncologist unfortunately doesn’t have at their fingertips the ability to measure metabolic tumor volume and soluble BCMA, which you can measure it in the peripheral blood. Increasingly these tests are going to become more routinely available. There have been a lot of publications put out about AI techniques that can automatically extract these features from imaging, and that’s only going to become more available as time goes on, and we’re working to develop and make those things easier to extract from standard of care images at Moffitt Cancer Center. And in addition, the testing that’s done is straightforward to do. We’ve already shown that instead of the laborious ELISA testing, which is the current way that researchers are measuring soluble BCMA in the lab, there’s actually faster, more high-throughput ways you can measure soluble BCMA, such as using the ELLA platform. We presented that data at the International Myeloma Society meeting last year. So hopefully in the very near future, these are tools that are going to be able to be utilized or at least incorporated into decision making. And as we’re showing here at this year’s meeting, if you layer these really important features onto the standard of care labs that we have, you can really improve your prognosticating power in terms of understanding who’s going to do really well and which patients might not do so well and might need an alternative treatment strategy or closer monitoring with CAR T-cell therapy. So I think it’s not quite in the hands of community oncologists yet but I think it is coming and definitely at bigger centers we’re going to try and make these tools available and share that information with the patients that we see and treat and share it with their local oncologists.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.